Literature DB >> 17344342

Humoral immune response after primary rubella virus infection and after vaccination.

C Vauloup-Fellous1, L Grangeot-Keros.   

Abstract

We measured rubella virus immunoglobulin G (IgG) and IgM levels, as well as IgG avidity indexes, in serum samples taken before or after 6 months either after infection or after vaccination. The results obtained indicate that humoral immune responses are different after primary infection and after vaccination. This may have important consequences on the serological diagnosis of rubella virus infection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17344342      PMCID： PMC1865636          DOI： 10.1128/CVI.00032-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  13 in total

Review 1.  Interpretation of rubella serology in pregnancy--pitfalls and problems.

Authors:  Jennifer M Best; Siobhan O'Shea; Graham Tipples; Nicholas Davies; Saleh M Al-Khusaiby; Amanda Krause; Louise M Hesketh; Li Jin; Gisela Enders
Journal:  BMJ       Date:  2002-07-20

2.  Maturation of rubella IgG avidity over time after acute rubella infection.

Authors:  B Böttiger; I P Jensen
Journal:  Clin Diagn Virol       Date:  1997-08

3.  Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19 and rubella infection.

Authors:  H I Thomas; E Barrett; L M Hesketh; A Wynne; P Morgan-Capner
Journal:  J Clin Virol       Date:  1999-10       Impact factor: 3.168

4.  Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy).

Authors:  P Morgan-Capner; N S Crowcroft
Journal:  Commun Dis Public Health       Date:  2002-03

5.  Rubella-specific serum and nasopharygeal immunoglobulin responses following naturally acquired and vaccine-induced infection. Prolonged persistence of virus-specific IgM.

Authors:  W Al-Nakib; J M Best; J E Banatvala
Journal:  Lancet       Date:  1975-01-25       Impact factor: 79.321

Review 6.  Rubella.

Authors:  J E Banatvala; D W G Brown
Journal:  Lancet       Date:  2004-04-03       Impact factor: 79.321

7.  Persistent rubella-specific IgM reactivity in the absence of recent primary rubella and rubella reinfection.

Authors:  H I Thomas; P Morgan-Capner; A Roberts; L Hesketh
Journal:  J Med Virol       Date:  1992-03       Impact factor: 2.327

8.  Development and persistence of class-specific antibodies in the serum and nasopharyngeal washings of rubella vaccinees.

Authors:  S O'Shea; J M Best; J E Banatvala; W M Shepherd
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226

9.  [Rubella vaccination: antibody persistence for 14-17 years and immune status of women without and with a history of vaccination].

Authors:  G Enders; U Nickerl
Journal:  Immun Infekt       Date:  1988-04

10.  Prenatal and postnatal production of IgM and IgA antibodies to rubella virus studied by antibody capture immunoassay.

Authors:  L Grangeot-Keros; J Pillot; F Daffos; F Forestier
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226
View more
  12 in total

1.  Rubella Surveillance and Diagnostic Testing among a Low-Prevalence Population, New York City, 2012-2013.

Authors:  Beth M Isaac; Jane R Zucker; Francesca R Giancotti; Emily Abernathy; Joseph Icenogle; Jennifer L Rakeman; Jennifer B Rosen
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

2.  Response to third rubella vaccine dose.

Authors:  Lotta Siira; Hanne Nøkleby; Regine Barlinn; Øystein R Riise; Ingeborg S Aaberge; Susanne G Dudman
Journal:  Hum Vaccin Immunother       Date:  2018-06-21       Impact factor: 3.452

3.  Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Clayton Harro; Ligia A Pinto
Journal:  Vaccine       Date:  2010-06-17       Impact factor: 3.641

4.  IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection.

Authors:  Rachael Racine; Maura McLaughlin; Derek D Jones; Susan T Wittmer; Katherine C MacNamara; David L Woodland; Gary M Winslow
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

5.  Development of a rapid and convenient method for determination of rubella virus-specific immunoglobulin G avidity.

Authors:  Christelle Vauloup-Fellous; Jessica Ursulet-Diser; Liliane Grangeot-Keros
Journal:  Clin Vaccine Immunol       Date:  2007-10-03

6.  Associations between markers of cellular and humoral immunity to rubella virus following a third dose of measles-mumps-rubella vaccine.

Authors:  Stephen N Crooke; Inna G Ovsyannikova; Richard B Kennedy; Nathaniel D Warner; Gregory A Poland
Journal:  Vaccine       Date:  2020-11-04       Impact factor: 3.641

Review 7.  Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies.

Authors:  Wayne Dimech; Liliane Grangeot-Keros; Christelle Vauloup-Fellous
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

Review 8.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

Review 9.  Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome.

Authors:  Megan K Young; Allan W Cripps; Graeme R Nimmo; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2015-09-09

10.  Preliminary multiplex microarray IgG immunoassay for the diagnosis of toxoplasmosis and rubella.

Authors:  Priscila T Baschirotto; Marco A Krieger; Leonardo Foti
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-06       Impact factor: 2.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.